ArticleCardiovascular diabetology2026
Proteomic signatures characterized by inflammatory signaling and metabolic processes have divergent associations with 30-year incidence of coronary artery disease in type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications cohort.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWhile inflammation is hypothesized to be a possible driver of the excess coronary artery disease (CAD) observed in type 1 diabetes, prior biomarker studies have focused on candidate proteins, overlooking the complex systemic processes underlying atherosclerosis. We thus applied a high-throughput proteomics approach to identify proteins prospectively associated with CAD in type 1 diabetes. We further hypothesized inflammatory proteins would partially mediate the effect of glycemic exposure on CAD risk.
methodsWe measured 184 circulating proteins (Olink CVD II and III panels) in earliest available serum samples from the Pittsburgh Epidemiology of Diabetes Complications cohort of childhood-onset (< 17 years) type 1 diabetes (n = 417, baseline mean age 30, mean diabetes duration 22 years). Protein modules were identified using weighted correlation network analysis. Prospective associations between modules (per eigenvalue SD) and 30-year incident hard CAD (hCAD; CAD death, nonfatal myocardial infarction, revascularization, or blockage ≥ 50%) were estimated in Cox models. Causal mediation analysis estimated mediation of the HbA1c-hCAD association by the modules.
resultsIncident hCAD occurred in 151 participants (36.2%). We identified three protein modules: one comprising 56 proteins, enriched for TNF/Notch signaling, T-cell activation, and necroptosis; another comprising 33 proteins, enriched for lipid catabolism, epithelial cell apoptosis, vitamin D response; and a third comprising 33 proteins, enriched for hemostasis, wound healing, and vascular growth factors. After adjusting for traditional covariates and HbA1c, greater abundance of proteins in the first module was associated with increased hCAD incidence (HR = 1.35, 95% CI: 1.06-1.72, p = 0.014) while the second module was protective (HR = 0.82, 95% CI: 0.70-0.96, p = 0.017). The third module was not associated with hCAD (HR = 1.03, 95%CI: 0.86-1.23, p = 0.751). The first module mediated 14% of the total HbA1c effect on hCAD.
conclusionsIn this prospective analysis of a type 1 diabetes cohort, a protein signature characterized by inflammatory signaling partially mediated the effect of hyperglycemia on hCAD, while a signature characterized by metabolic processes including lipid catabolism and hormone response was associated with hCAD protection independent of glycemia. These findings move beyond single-marker associations, identifying distinct protein signatures that warrant further study as intervention targets for CAD prevention in type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.